Medical Cannabis and Cannabinoids,
Journal Year:
2024,
Volume and Issue:
7(1), P. 51 - 58
Published: Feb. 20, 2024
<b><i>Introduction:</i></b>
The
development
of
a
novel
dosage
form
for
cannabis
extract
is
necessary
to
improve
drug
delivery
and
also
enhance
patient
convenience.
<b><i>Methods:</i></b>
Orally
fast-disintegrating
wafer
tablets
containing
extract,
which
were
prepared
using
the
freeze
drying
technique,
developed
in
this
work.
formulation
consisted
several
key
components:
as
active
compound,
Tween<sup>®</sup>
80
surfactant
solubilizer,
gelatin
mannitol
structural
components,
sucralose
sweetening
agent,
sodium
methylparaben
propylparaben
preservatives.
<b><i>Results:</i></b>
optimized
consists
following
ingredients:
5%
1.25%
80,
gelatin,
88.34%
mannitol,
0.2%
sucralose,
0.19%
methylparaben,
0.02%
propylparaben.
resulting
exhibited
characteristics:
porous
structure,
an
average
weight
approximately
200
mg,
minimal
variation
(less
than
1.4%),
slightly
acidic
pH
(pH
5.12),
disintegration
within
10
s,
low
moisture
content
3%),
Δ<sup>9</sup>-tetrahydrocannabinol
2.8
cannabidiol
0.9
mg.
Additionally,
rapidly
dissolved
simulated
saliva
fluid
lauryl
sulfate.
<b><i>Conclusion:</i></b>
This
work
succeeded
fabrication
orally
with
desired
properties.
Life,
Journal Year:
2022,
Volume and Issue:
12(5), P. 652 - 652
Published: April 27, 2022
Cannabidiol
(CBD)
is
the
second
cannabinoid,
in
order
of
importance
after
Δ9-tetrahydrocannabinol
(THC),
from
Cannabis
sativa.
Unlike
THC,
CBD
does
not
cause
psychotomimetic
effects,
and
although
these
compounds
have
same
chemical
formula,
their
pharmacological
characteristics
are
equivalent.
Preclinical
studies
suggest
that
has
anti-inflammatory,
analgesic,
anxiolytic,
antiemetic,
anticonvulsant,
antipsychotic
properties
influences
sleep–wake
cycle.
The
evaluation
effects
on
spontaneous
motor
activity
crucial
experimental
pharmacology,
careful
measurement
laboratory
animal
movement
an
established
method
to
recognize
stimulant
depressant
drugs.
potential
influence
locomotor
been
investigated
through
numerous
vivo
experiments.
However,
there
no
clear
picture
impact
issues,
even
though
it
administered
alone
for
medical
uses
sold
with
THC
as
a
drug
pain
caused
by
muscle
spasms
multiple
sclerosis,
was
recently
licensed
severe
forms
infantile
epilepsy.
On
this
basis,
aim
developing
deeper
knowledge
issue,
scientific
data
CBD’s
discussed
here.
We
conducted
research
using
PubMed,
Scopus,
Google
Scholar,
search
engine
literature
between
January
2009
December
2021
life
sciences
biomedical
topics
keywords
“motor
activity”,
“locomotor
“locomotion”
combination
“cannabidiol”.
In
article,
we
discuss
findings
describing
precursor
cannabidiolic
acid
or
together
modifications
induced
diseases
changes
other
substances.
The Veterinary Journal,
Journal Year:
2023,
Volume and Issue:
296-297, P. 105990 - 105990
Published: May 6, 2023
Drug
resistance
continues
to
be
a
major
clinical
problem
in
the
therapeutic
management
of
canine
epilepsies
with
substantial
implications
for
quality
life
and
survival
times.
Experimental
data
from
human
medicine
provided
evidence
relevant
contributions
intrinsic
severity
disease
as
well
alterations
pharmacokinetics
-dynamics
failure
respond
antiseizure
medications.
In
addition,
several
modulatory
factors
have
been
identified
that
can
associated
level
responses.
Among
others,
list
potential
comprises
genetic
epigenetic
factors,
inflammatory
mediators,
metabolites.
Regarding
dogs,
there
are
obvious
gaps
knowledge
when
it
comes
our
understanding
patterns
mechanisms
drug-resistant
epilepsy.
So
far,
seizure
density
occurrence
cluster
seizures
linked
poor
response
Moreover,
exists
background
might
influence
efficacy
medications
dogs
Further
molecular,
cellular,
network
may
affect
severity,
pharmacokinetics,
reported.
However,
association
drug
responsiveness
has
not
yet
studied
detail.
summary,
is
an
urgent
need
strengthen
experimental
research
efforts
exploring
their
different
etiologies,
epilepsy
types,
courses.
Neuroscience Research,
Journal Year:
2022,
Volume and Issue:
unknown
Published: Oct. 1, 2022
Major
depressive
disorder,
one
of
the
most
widespread
mental
illnesses,
brings
about
enormous
individual
and
socioeconomic
consequences.
Conventional
monoaminergic
antidepressants
require
weeks
to
months
produce
a
therapeutic
response,
approximately
one-third
patients
fail
respond
these
drugs
are
considered
treatment-resistant.
Although
recent
studies
have
demonstrated
that
ketamine,
an
N-methyl-D-aspartate
receptor
antagonist,
produces
rapid
antidepressant
effects
in
treatment-resistant
patients,
it
also
has
undesirable
side
effects.
Hence,
rapid-acting
fewer
adverse
than
ketamine
urgently
required.
D-series
(RvD1-RvD6)
E-series
(RvE1-RvE4)
resolvins
endogenous
lipid
mediators
derived
from
docosahexaenoic
eicosapentaenoic
acids,
respectively.
These
reportedly
play
pivotal
role
resolution
acute
inflammation.
In
this
review,
we
reveal
intracranial
infusions
RvD1,
RvD2,
RvE1,
RvE2,
RvE3
antidepressant-like
various
rodent
models
depression.
Moreover,
behavioral
RvE1
mediated
by
activation
mechanistic
target
rapamycin
complex
1,
which
is
essential
for
actions
ketamine.
Finally,
briefly
provide
our
perspective
on
possible
stress
resilience.
British Journal of Cancer,
Journal Year:
2023,
Volume and Issue:
130(1), P. 19 - 30
Published: Oct. 26, 2023
Abstract
The
side
effects
of
cancer
therapy
continue
to
cause
significant
health
and
cost
burden
the
patient,
their
friends
family,
governments.
A
major
barrier
in
way
which
these
are
managed
is
highly
siloed
mentality
that
results
a
fragmented
approach
symptom
control.
Increasingly,
it
appreciated
many
symptoms
manifestations
common
underlying
pathobiology,
with
changes
gastrointestinal
environment
key
driver
for
sequelae.
Breakdown
mucosal
(mucositis)
early
effect
anti-cancer
agents,
known
contribute
(in
part)
range
burdensome
such
as
diarrhoea,
nausea,
vomiting,
infection,
malnutrition,
fatigue,
depression,
insomnia.
Here,
we
outline
rationale
how,
based
on
its
already
documented
microenvironment,
medicinal
cannabis
could
be
used
control
mucositis
prevent
constellation
associated.
We
will
provide
brief
update
current
state
evidence
care
potential
benefits
(and
challenges)
using
during
active
therapy.
Cannabis and Cannabinoid Research,
Journal Year:
2022,
Volume and Issue:
8(1), P. 119 - 125
Published: Feb. 23, 2022
Cannabidiol
(CBD)
is
one
of
the
most
abundant
components
Cannabis
and
has
long
been
used
in
Cannabis-based
preparations.
Recently,
CBD
become
a
promising
pharmacological
agent
because
its
beneficial
properties
pathophysiology
several
diseases.
Although
kind
cannabinoid
acts
on
receptors
(CB1
CB2),
molecular
targets
involved
diverse
therapeutic
have
not
identified
also
interacts
with
other
targets.
Considering
that
alters
intracellular
calcium
level
by
which
calpain
activity
controlled,
both
are
associated
various
diseases
related
to
signaling,
including
neurological
disorders,
this
review
provides
an
overview
signaling
as
possible
CBD.
As
known
play
important
role
disease,
deeper
understanding
relationship
will
be
meaningful.
To
understand
regulator,
silico
structural
analysis
binding
mode
was
performed.
Journal of Gastroenterology and Hepatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 3, 2024
Abstract
There
is
increasing
evidence
that
cannabidiol
(CBD)
use
associated
with
clinically
significant
liver
enzyme
(LE)
elevations
and
drug‐induced
injury
(DILI).
The
proportion
of
LE
DILI
events
reported
in
the
literature
meet
Council
for
International
Organizations
Medical
Sciences'
(CIOMS)
classification
a
common
adverse
drug
reaction.
However,
these
potential
are
unknown
to
many
clinicians
may
be
overlooked.
CBD
both
medical
non‐medical
necessitates
clear
direction
diagnosis
management
CBD‐associated
hepatotoxicity.
To
our
knowledge,
no
such
clinical
guidance
currently
exists.
For
people
presenting
elevated
LEs,
should
screened
considered
differential
diagnosis.
This
narrative
review
will
provide
prevention,
detection,
CBD‐related
